New drug combo trial targets tough liver and bile duct cancers

NCT ID NCT07111546

Recruiting now Disease control Sponsor: Nanjing Leads Biolabs Co.,Ltd Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new drug called LBL-024, when combined with other cancer drugs, can help control advanced liver cancer and bile duct cancer. It will enroll about 140 patients to see if the treatment shrinks tumors and is safe. The trial is in Phase 2, meaning researchers are gathering more evidence on how well it works.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450008, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Jiangxi Cancer Hospital
RECRUITING

Nanchang, Jiangxi, 330029, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Sir Run Run Shaw Hospital (SRRSH) Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310016, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Xiangyang Central Hospital
NOT_YET_RECRUITING

Xiangyang, Hubei, 441106, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Zhongshan Hospital of Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOUR